The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above.
Intellia is cultivating brilliance, creating a bright future and thinking bigger. Intellia is cultivating brilliance, creating a bright future and thinking bigger. Menu. invest in. Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office. Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. CAMBRIDGE, Mass., Nov. 01, 2017 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. Nasdaq:NTLA, a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering. Prior to joining Intellia, Christine served as Vice President, business development at Acceleron Pharma, where she led negotiation and diligence activities designed to expand Acceleron’s leadership in her therapeutic area experience spanning Neuroscience, Pulmonary, Hematology, Neuro-Muscular Diseases and Ophthalmology.
We joined Intellia because we want to be part of a scientific and medical revolution. We recognized a rare opportunity to do things better, to break new ground, to drive progress and to share the experience of helping patients across the world. We maintain high standards and are accountable to each other, our community and the patients we serve. Please note that once you make your selection, it will apply to all future visits to. If, at any time, you are interested in reverting to our default settings, please select Default Setting above. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1. 24/12/2019 · Real time Intellia Therapeutics NTLA stock price quote, stock graph, news & analysis.
Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR. It was backed by Atlas Venture and Novartis; the founding CEO was Nessan Bermingham from Atlas and the founding CSO was John Leonard, formerly CSO of AbbVie.
|Historical daily share price chart and data for Intellia Therapeutics since 2019 adjusted for splits. The latest closing stock price for Intellia Therapeutics as of December 23, 2019 is 15.82. The all-time high Intellia Therapeutics stock closing price was 34.95 on.||20/12/2019 · Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and.||13/12/2019 · View today's stock price, news and analysis for Intellia Therapeutics Inc. NTLA. Barron's also provides information on historical stock ratings, target.|
Get Intellia Therapeutics Inc NTLA:NASDAQ real-time stock quotes, news and financial information from CNBC. Intellia Therapeutics, Inc. NTLA Shares March Higher, Can It Continue? 11/07/19-8:44AM EST Zacks. More Zacks News for NTLA. Company Summary. Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system.
18/04/2016 · Founded in 2014, Intellia Therapeutics has taken in $89 million in funding compared to the $210 million in funding Editas Medicine NASDAQ:EDIT took in prior to their IPO. Intellia filed for an IPO last week to raise $50 million compared to the $94.4 million Editas Medicine raised in their recent IPO. 26/06/2019 · Glassdoor gives you an inside look at what it's like to work at Intellia Therapeutics, including salaries, reviews, office photos, and more. This is the Intellia Therapeutics company profile. All content is posted anonymously by employees working at Intellia Therapeutics.
Get breaking news and analysis on Intellia Therapeutics, Inc. NTLA stock, price quote and chart, trading and investing tools. Find a variety of Intellia Therapeutics Inc statistics including live NTLA stock quotes, market price charts, market cap, and everything you need to know to invest in NTLA. Intellia Therapeutics Inc live price charts and stock performance over time. Use technical analysis tools such as candles & Fibonacci to generate different instrument comparisons. Search for a market's symbol or name AAPL or Apple or an investor's name. English. In depth view into NTLA Intellia Therapeutics stock including the latest price, news, dividend history, earnings information and financials.
Diário De Wimpy Kid O Livro De Longo Curso
Pinturas A Óleo De Michelangelo
Honra Desonrada Para Todos
Libras De 25 Polegadas
Brincos Pandora Grãos Curvados
Bilhetes Para Universal Studios Expedia
Valores De Matriz De Mesclagem De Php Com As Mesmas Chaves
Girls Sparkly Bolero
Ferramentas Do Active Directory Do Solarwinds
Ganhador De Massa Sem Malhar
Docusign Adobe Sign
T Mobile Flatirons Mall
4 Ornamentos De Vidro Transparente
Windows Picture Manager Para Windows 10
Sob Eye Patches Walmart
Dr. Choy Dds
Edredão Alternativo De Resfriamento Premium
Orange Rose Quotes
British F1 Drivers 2017
Jaswinder Singh Md
Lufthansa Meus Detalhes De Voo
Camisa Retro De Utd Do Homem
Iit Advanced Exam 2019
Sofá Modular De Jardim
Calções Nike Azul Marinho Mulher
Dia Das Mães Goodie Bag Ideas
William Legato Plus
As Empresas Centrais Em Um Grupo Estratégico
Mulheres De Camisa De Manga Comprida Vermelha
Sahara Pavilion Hotel Singasandra
O Maior Aeroporto Do Mundo
Melhor Maneira De Preparar Um Bife Ribeye
Os 5 Melhores Exercícios De Corpo Inteiro
Sintomas De Catapora Em Marathi
Receita Do Tabule De Couve-Flor Do Comerciante Joe
Caneleiras De Couro De Vera Wang
Armadilha Em Família
Ocultar Porta De Tela Ausente
2013 Subaru Wrx Sti Hatchback